Austrian Breast

Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.

R. Greil, J. Cuzick, T. Nielsen, 2013 .

Prognostic and Predictive Value of the Tumor-Stroma Ratio in STAGE II Colon Cancer

R. Greil, R. Tollenaar, M. Gnant, 2020, Clinical Oncology and Research.

Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).

R. Greil, M. Gnant, R. Jakesz, 2010 .

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).

M. Rezai, P. Fasching, A. Schneeweiss, 2016, European journal of cancer.